FDA Notifications
FDA grants approval of generic lamivudine tablets
On Aug. 6, 2009, the FDA granted tentative approval for a generic formulation of lamivudine tablets, 150 mg and 300 mg, manufactured by Strides Arcolab Limited of Bangalore, India, indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).
"Tentative approval" means that the FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for consideration for purchase outside the United States under the PEPFAR program.
As with all generic applications, the FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.
This product is a generic formulation of Epivir tablets, 150 mg and 300 mg, a Nucleoside Reverse Transcriptase Inhibitor (NRTI) manufactured by GlaxoSmithKline. Patent and exclusivity Information about this product is available in the FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan on the FDA web site.
Generic efavirenz capsules tentatively approved by FDA
On Aug. 3, 2009, the Food and Drug Administration granted tentative approval for a generic formulation of efavirenz capsules, 200 mg, manufactured by Cipla, Limited, of Mumbai, India, indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).
This product is a generic version of Sustiva© capsules, 200 mg, a Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), manufactured by Bristol Myers-Squibb. Effective patent dates can be found in the FDA publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the "Orange Book."
As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.
On Aug. 6, 2009, the FDA granted tentative approval for a generic formulation of lamivudine tablets, 150 mg and 300 mg, manufactured by Strides Arcolab Limited of Bangalore, India, indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.